Isofol Medical AB (publ) (FRA:5IU)

Market Cap	15.41M -48.8%
Revenue (ttm)	n/a
Net Income	-5.01M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0415
Previous Close	0.0402
Day's Range	0.0415 - 0.0415
52-Week Range	0.0402 - 0.1764
Beta	n/a
RSI	39.34
Earnings Date	Feb 18, 2026

About Isofol Medical AB

Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2008
• Employees: 6
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5IU

Financial Performance

Financial numbers in SEK